# US 2004/0072786 A1 · Antisense oligonucleotide inhibition of ras

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072786 A1
- Document ID: US20040072786A1
- Status: Published application
- Kind: A1
- Application number: 10/643,130
- Filed: 2003-08-18
- Published: 2004-04-15
- Earliest claimed: 1992-10-05
- Inventors: Brett P. Monia; Lex M. Cowsert; Muthiah Manoharan; F. Andrew Dorr; Jon Holmlund
- Web page: https://patentgrep.com/patent/US20040072786A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/282: Platinum compounds
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 33/243: Platinum; Compounds thereof
- C07K 14/82: Translation products from oncogenes
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/333: Modified A
- C12N 2310/3521: Methyl
- C12N 2310/3527: Other alkyl chain
- C12N 2310/3533: Halogen
- C12Q 2525/125: incorporating agents resulting in resistance to degradation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Compositions and are provided which are targeted to nucleic acids methods are provided for the modulation of ras expression. Oligonucleotides encoding human ras. Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions, or particular cancers, associated with ras are also disclosed.

## Claims

### Claim 1

A composition comprising an oligonucleotide 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human ras, and which is capable of inhibiting ras expression, and at least one chemotherapeutic agent.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said oligonucleotide is targeted to mRNA encoding human H-ras.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said oligonucleotide is targeted to mRNA encoding human Ki-ras.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said oligonucleotide is targeted to mRNA encoding human N-ras.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said oligonucleotide is targeted to a 5′ untranslated region, translation initiation site, coding region or 3′ untranslated region of an mRNA encoding human N-ras.

### Claim 6 (depends on 4)

The composition of claim 4, wherein said oligonucleotide has the sequence shown in SEQ ID NO: 2.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said oligonucleotide comprises at least one backbone modification.

### Claim 8 (depends on 1)

The composition of claim 1, wherein at least one of the nucleotide units of said oligonucleotide is modified at the 2′ position of the sugar.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said oligonucleotide is a chimeric oligonucleotide.

### Claim 10 (depends on 1)

The composition of claim 1, wherein said chemotherapeutic agent is selected from the group consisting of daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, magosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydrosyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 50fluorodeoxyuridine (5-FudR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES).

### Claim 11 (depends on 1)

The composition of claim 1 in a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A method of modulating the expression of human ras comprising contacting tissues or cells containing a human ras gene with an effective amount of the composition of claim 1, whereby expression of ras is modulated.

### Claim 13 (depends on 1)

A method of inhibiting the proliferation of cancer cells comprising contacting cancer cells with an effective amount of the composition of claim 1, whereby proliferation of the cancer cells is inhibited.

### Claim 14 (depends on 13)

The method of claim 13 wherein the cells are blood cells.

### Claim 15 (depends on 13)

The method of claim 13 wherein the cells are peripheral blood mononuclear cells.

### Claim 16 (depends on 1)

A method of preventing or treating a condition arising from the activation of a ras oncogene comprising contacting an animal suspected of having a condition arising from the activation of a ras oncogene with an effective amount of the composition of claim 1, whereby said condition is prevented or treated.

### Claim 17 (depends on 16)

The method of claim 16 wherein said activation of a ras oncogene is abnormal expression of a ras oncogene.

### Claim 18 (depends on 16)

The method of claim 16 wherein said condition is a hyperproliferative condition.

### Claim 19 (depends on 16)

The method of claim 16 wherein the condition is cancer.

### Claim 20 (depends on 16)

The method of claim 16 wherein the condition is colorectal cancer, melanoma, liposarcoma, mesothelioma, sarcoma, colon cancer, or pancreatic cancer.
